The final results are dependent on the model of hypertension, age, sex, the cannabinoid ligands used or the action via endocannabinoid metabolites. We discuss pleiotropic effects of cannabinoids on the cardiovascular system mediated via numerous neuronal and non‐neuronal mechanisms both in normotension and in hypertension. We underline differences between the acute cannabinoid administration and their potential hypotensive effect after chronic application in experimental hypertension. In this paper, we present limited clinical data concerning the role of cannabinoids in human hypertension including polymorphism of endocannabinoid system components.
The endocannabinoid system is overactivated in arterial, pulmonary and portal hypertension.
0 kommentar(er)
